Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
332.8 INR | +9.01% | +2.83% | +33.29% |
May. 31 | Biocon Limited Receives Show Cause Notice from the Assistant Commissioner of Customs, Chennai | CI |
May. 24 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 71% by 2026.
- The company's profit outlook over the next few years is a strong asset.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.34 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.47 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.29% | 4.37B | A- | ||
+18.77% | 125B | B+ | ||
+14.75% | 109B | B+ | ||
-3.02% | 24.74B | B+ | ||
+3.00% | 22.67B | B | ||
-9.91% | 18.14B | A- | ||
-41.04% | 16.67B | A- | ||
-12.40% | 16.64B | B | ||
+0.93% | 13.45B | C+ | ||
+22.65% | 11.32B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIOCON Stock
- Ratings Biocon Limited